Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03493685 · ClinicalTrials.gov registry record · Phase 3

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

A Phase 3 study of Focal Segmental Glomerulosclerosis, sponsored by Travere Therapeutics.

Active
Registry status
Phase 3
Development phase
371
Enrollment target
20
Study locations

NCT03493685 is a Phase 3 study of Focal Segmental Glomerulosclerosis that is active but no longer recruiting, run by Travere Therapeutics. The registered enrollment target is 371 participants, above the 217-participant average among 19 other Focal Segmental Glomerulosclerosis trials with a reported enrollment target (71% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03493685, a Phase 3 study of Focal Segmental Glomerulosclerosis, is active but no longer recruiting, sponsored by Travere Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
371 participants
Enrollment target
20
Study locations

Study Summary

To determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary and genetic focal segmental glomerulosclerosis (FSGS).

Conditions Studied

Focal Segmental Glomerulosclerosis

Interventions

  • DRUG sparsentan
  • DRUG Irbesartan

Study Locations (20)

California

  • Travere Investigational Site - Los Angeles
  • Travere Investigational Site - Northridge
  • Travere Investigational Site - Palo Alto
  • Travere Investigational Site - San Diego
  • Travere Investigational Site - San Dimas
  • Travere Investigational Site - San Francisco
  • Travere Investigational Site - Torrance
  • Travere Investigational Site - Victorville

Florida

  • Travere Investigational Site - Coral Springs
  • Travere Investigational Site - Fort Lauderdale
  • Travere Investigational Site - Gainesville
  • Travere Investigational Site - Miami
  • Travere Investigational Site - Miami

Arizona

  • Travere Investigational Site - Mesa
  • Travere Investigational Site - Phoenix

Colorado

  • Travere Investigational Site - Denver
  • Travere Investigational Site - Denver

Connecticut

  • Travere Investigational Site - Middlebury

Delaware

  • Travere Investigational Site - Wilmington

District of Columbia

  • Travere Investigational Site - Washington D.C.

Trial Details

FieldValue
Enrollment Target 371 participants
Start Date 2018-04-17
Est. Completion 2026-02
Phase Phase 3

Sponsor

Travere Therapeutics

12 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03493685

The ClinicalTrials.gov registry entry for NCT03493685 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 371 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 217-participant average among 19 other Focal Segmental Glomerulosclerosis trials with a reported enrollment target (71% higher). The listed sponsor is Travere Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Focal Segmental Glomerulosclerosis appearing as the primary indexed condition, and to 2 interventions - of which sparsentan is the first listed.

NCT03493685 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT03493685 about?

NCT03493685 is a clinical study titled "Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)". To determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary and genetic focal segmental glomerulosclerosis (FSGS).

What is the current status of trial NCT03493685?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 371 participants. The study started on 2018-04-17. Estimated completion is 2026-02.

What conditions does trial NCT03493685 study?

This clinical trial studies the following conditions: Focal Segmental Glomerulosclerosis.

What interventions are being tested in trial NCT03493685?

The interventions under investigation include: sparsentan (DRUG), Irbesartan (DRUG).

Who is sponsoring clinical trial NCT03493685?

This trial is sponsored by Travere Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03493685 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Focal Segmental Glomerulosclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Focal Segmental Glomerulosclerosis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.